Background Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the …

Background: No effective oral therapy exists for early coronavirus disease 2019 (COVID-19).
Objective: To investigate whether hydroxychloroquine could reduce COVID-19 severity in …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral
infection causing coronavirus disease 2019 (COVID-19). Hydroxychloroquine and …

The landscape of clinical mycology is constantly changing. New therapies for malignant and
autoimmune diseases have led to new risk factors for unusual mycoses. Invasive …

The global burden of the endemic mycoses (blastomycosis, coccidioidomycosis, emergomycosis,
histoplasmosis, paracoccidioidomycosis, sporotrichosis, and talaromycosis) continues …

Coronavirus disease 2019 (COVID-19) can become complicated by secondary invasive
fungal infections (IFIs), stemming primarily from severe lung damage and immunologic deficits …

Endemic mycoses such as histoplasmosis, coccidioidomycosis, blastomycosis,
paracoccidioidomycosis, and talaromycosis are well-known causes of focal and systemic disease …

Background: Few studies have examined culture’s effect on pediatric care. Objectives: To
analyze 3 cases illustrating the importance of culture in pediatrics. Methods: Case analysis …

Fungal endocarditis accounts for 1% to 3% of all infective endocarditis cases, is associated
with high morbidity and mortality (>70%), and presents numerous challenges during clinical …

Recent discoveries of novel systemic fungal pathogens with thermally dimorphic yeast‐like
phases have challenged the current taxonomy of the Ajellomycetaceae, a family currently …